ReviewJournal of neural transmission. Supplementum2006
Pathology associated with sporadic Parkinson's disease--where does it end?
Review in Journal of neural transmission. Supplementum, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 181 citations in OpenAlex.
- Co- and Multi-Pathologies in Parkinson's Disease: An International Parkinson and Movement Disorder Society Scientific Issues Committee Review.Movement disorders : official journal of the Movement Disorder Society · 2026Review
- Standardization of postmortem human brainstem along the rostrocaudal axis to accommodate for inter-specimen structural heterogeneity.Scientific reports · 2025Article
- Searching for the cellular underpinnings of the selective vulnerability to tauopathic insults in Alzheimer's disease.Communications biology · 2025Article
- Current insights and assumptions on α-synuclein in Lewy body disease.Acta neuropathologica · 2024Review
- Understanding the role of cerebellum in early Parkinson's disease: a structural and functional MRI study.NPJ Parkinson's disease · 2024Article
- Single-domain antibodies and aptamers drive new opportunities for neurodegenerative disease research.Frontiers in immunology · 2024Review
- Advancing Parkinson's Disease Research in Canada: The Canadian Open Parkinson Network (C-OPN) Cohort.Journal of Parkinson's disease · 2024Article
- Cellular underpinnings of the selective vulnerability to tauopathic insults in Alzheimer's disease.bioRxiv : the preprint server for biology · 2023Article
- Neurodegenerative pathologies associated with behavioral and psychological symptoms of dementia in a community-based autopsy cohort.Acta neuropathologica communications · 2023Article
- Dysphagia in Parkinson Disease: Part I - Pathophysiology and Diagnostic Practices.Current physical medicine and rehabilitation reports · 2023Article
- Urinary Incontinence in a Community-Based Autopsy Cohort Is Associated with Limbic Predominant Age-Related TDP-43 Encephalopathy Neuropathologic Changes.Journal of Alzheimer's disease : JAD · 2023Article
- Pathogenesis of α-Synuclein in Parkinson's Disease: From a Neuron-Glia Crosstalk Perspective.International journal of molecular sciences · 2022Review
- Role of the Gut-Brain Axis, Gut Microbial Composition, Diet, and Probiotic Intervention in Parkinson's Disease.Microorganisms · 2022Review
- Lewy body disease or diseases with Lewy bodies?NPJ Parkinson's disease · 2022Review
- Associations of Sleep Disorders With Depressive Symptoms in Early and Prodromal Parkinson's Disease.Frontiers in aging neuroscience · 2022Article
- PINK1 kinase dysfunction triggers neurodegeneration in the primate brain without impacting mitochondrial homeostasis.Protein & cell · 2022Article
- Transient receptor potential V1 modulates neuroinflammation in Parkinson's disease dementia: Molecular implications for electroacupuncture and rivastigmine.Iranian journal of basic medical sciences · 2021Article
- The gut microbiota-brain axis in behaviour and brain disorders.Nature reviews. Microbiology · 2021Review
- Review
- Roles of Motor Cortex Neuron Classes in Reach-Related Modulation for Hemiparkinsonian Rats.Frontiers in neuroscience · 2021Article
9 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD) is a multisystem disorder in which predisposed neuronal types in specific regions of the human peripheral, enteric, and central nervous systems become progressively involved. A staging procedure for the PD-related inclusion body pathology (i.e., Lewy neurites and Lewy bodies) in the brain proposes that the pathological process begins at two sites and progresses in a topographically predictable sequence in 6 stages. During stages 1-2, the inclusion body pathology remains confined to the medulla oblongata, pontine tegmentum, and anterior olfactory structures. In stages 3-4, the basal mid- and forebrain become the focus of the pathology and the illness reaches its symptomatic phase. In the final stages 5-6, the pathological process is seen in the association areas and primary fields of the neocortex. To date, we have staged a total of 301 autopsy cases, including 106 cases with incidental pathology and 176 clinically diagnosed PD cases. In addition, 163 age-matched controls were examined. 19 of the 301 cases with PD-related pathology displayed a pathological distribution pattern of Lewy neurites and Lewy bodies that diverged from the staging scheme described above. In these cases, olfactory structures and the amygdala were predominantly involved in the virtual absence of brain stem pathology. Most of the divergent cases (17/19) had advanced concomitant Alzheimer's disease-related neurofibrillary changes (stages IV-VI).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.